Sugi Predict

Sugi Predict / Compounds / SCHEMBL6930829

SCHEMBL6930829

SCHEMBL6930829

CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1ccc(NC(=O)c2ccccc2)nc1=O

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ P2RY6 Q15077 6/20 0.60
▸ P2RY14 Q15391 2/20 0.60
▸ NT5E P21589 1/20 0.60
▸ POLB P06746 1/20 0.58
▸ ABL1 P00519 1/20 0.56
▸ RIN1 Q13671 1/20 0.56
▸ LMNA P02545 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ MTOR P42345 1/20 0.47
▸ MDM2 Q00987 1/20 0.47
▸ NCOA1 Q15788 1/20 0.47
▸ NCOA3 Q9Y6Q9 1/20 0.47
▸ P2RY2 P41231 3/20 0.44
▸ P2RY4 P51582 3/20 0.44
▸ MAPT P10636 1/20 0.43
▸ CDA P32320 1/20 0.43
▸ ST6GAL1 P15907 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6930835 1.00 P2RY6 (0.60) P2RY6P2RY14NT5EPOLBABL1
SCHEMBL19841274 1.00 P2RY6 (0.60) P2RY6P2RY14NT5EPOLBABL1
SCHEMBL14429055 0.96 P2RY6 (0.61) P2RY6P2RY14NT5EPOLBABL1
SCHEMBL14440571 0.96 P2RY6 (0.61) P2RY6P2RY14NT5EPOLBABL1
SCHEMBL15691436 0.93 P2RY6 (0.61) P2RY6P2RY14NT5EPOLBABL1
SCHEMBL12404718 0.93 P2RY6 (0.60) P2RY6P2RY14NT5EPOLBABL1
SCHEMBL31274927 0.92 P2RY6 (0.59) P2RY6P2RY14NT5EPOLBABL1
SCHEMBL30657735 0.92 P2RY6 (0.59) P2RY6P2RY14NT5EPOLBABL1
SCHEMBL29392593 0.91 POLB (0.66) P2RY6P2RY14NT5EPOLBABL1
SCHEMBL12404750 0.91 POLB (0.66) P2RY6P2RY14NT5EPOLBABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746905-A1 RSV VACCINE Astrazeneca AB (SE) 2026-05-27 — — EP disclosed
EP-4741411-A2 OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2026-05-13 — — EP disclosed
US-20250312367-A1 OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF ADARX PHARMACEUTICALS, INC. (US) 2025-10-09 — — US disclosed
US-12269841-B2 Production method for oligonucleotides AJINOMOTO CO., INC. (JP) 2025-04-08 — — US disclosed
EP-4522628-A2 OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF Adarx Pharmaceuticals, Inc. (US) 2025-03-19 — — EP disclosed
US-20250041400-A1 RSV VACCINE ASTRAZENECA PHARMACEUTICALS LP 2025-02-06 — — US disclosed
WO-2025017142-A1 RSV VACCINE ASTRAZENECA AB (SE) 2025-01-23 — — WO disclosed
CN-118834255-A Novel modified nucleotide and application thereof in RNAi (ribonucleic acid interference) medicament 纳肽得(青岛)生物医药有限公司 2024-10-25 — — CN disclosed
US-20240018180-A1 OLIGONUCLEOTIDE PRODUCTION METHOD AJINOMOTO CO., INC. (JP) 2024-01-18 — — US disclosed
EP-4293035-A1 OLIGONUCLEOTIDE PRODUCTION METHOD AJINOMOTO CO., INC. (JP) 2023-12-20 — — EP disclosed
US-6242592-B1 Process for the preparation of 2′-O-alkyl-guanosine, cytidine, and uridine phosphoramidites ISIS PHARMACEUTICALS, INC. 2001-06-05 — — US disclosed
US-6133438-A Process for the preparation of 2'-O-alkyl purine phosphoramidites ISIS PHARMACEUTICALS, INC. (US) 2000-10-17 — — US disclosed
US-5914396-A 2'-O-modified nucleosides and phosphoramidites ISIS PHARMACEUTICALS, INC. (US) 1999-06-22 — — US disclosed
US-5856466-A Process for the preparation of 2'-O-alkyl purine phosphoramidites ISIS PHARMACEUTICALS, INC. (US) 1999-01-05 — — US disclosed
US-5646265-A Process for the preparation of 2'-O-alkyl purine phosphoramidites ISIS PHARMCEUTICALS, INC. (US) 1997-07-08 — — US disclosed
EP-0651759-A4 NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. ISIS PHARMACEUTICALS INC (US) 1995-10-25 — — EP disclosed
EP-0651759-A1 NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF ISIS PHARMACEUTICALS, INC. (US) 1995-05-10 — — EP disclosed
WO-1994002501-A1 NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF ISIS PHARMACEUTICALS, INC. (US) 1994-02-03 — — WO disclosed
EP-0260032-B1 Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers AJINOMOTO KK (JP) 1994-01-26 — — EP disclosed
EP-0320103-A2 Compounds for DNA deletion and oligomers used therefor as well as a method for use thereof AJINOMOTO CO., INC. (JP) 1989-06-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250312367-A1 OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF POLRMT, TARDBP, NSUN2 P2RY6 2563/4885P2RY14 2588/4885NT5E 163/4885
US-20250041400-A1 RSV VACCINE LSS, SLFN12, FDPS P2RY6 4720/4885P2RY14 4373/4885NT5E 3529/4885
US-20240018180-A1 OLIGONUCLEOTIDE PRODUCTION METHOD RNGTT, NOX4, POLRMT P2RY6 2109/4885P2RY14 2303/4885NT5E 897/4885
US-12269841-B2 Production method for oligonucleotides RNGTT, DCLRE1B, PHOSPHO1 P2RY6 2497/4885P2RY14 3336/4885NT5E 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.